Improved Treatment and Monitoring of Alzheimer's Disease

NCT07135245 on ClinicalTrials.gov · last registry update 2025-08-22

Registered but not yet open, with 180 participants planned. Due to report 30 September 2030, alongside 5 other tracked readouts that quarter. Primary outcome, as filed: The Montreal Cognitive Assessment. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Rune Skovgaard Rasmussen
Sponsor type: Other
Enrollment: 180
Started: 2026-01-01
Primary completion: 2030-09-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The Montreal Cognitive Assessment

Conditions studied

Alzheimer Disease (AD)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.